Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys

Vaccine

Volumn 27, Issue 10, 2009, Pages 1549-1556

  Grandpre, Lauren E ^a   Duke Cohan, Jonathan S ^b,d   Ewald, Bonnie A ^a   Devoy, Colleen ^a   Barouch, Dan H ^a,d   Letvin, Norman L ^a,d   Reinherz, Ellis L ^b,d   Baden, Lindsey R ^a,c,d   Dolin, Raphael ^a,d   Seaman, Michael S ^a,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

MVA; Neutralizing antibody; Rhesus monkey; Vaccine; Vaccinia virus

Indexed keywords

ANTIGEN; DNA VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT MODIFIED VACCINIA ANKARA VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; RHESUS MONKEY; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS REACTIONS; DEFECTIVE VIRUSES; FOWLPOX VIRUS; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MACACA MULATTA; NEUTRALIZATION TESTS; SMALLPOX VACCINE; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 60349131089     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.010     Document Type: Article

References (37)

1. Fenner F. The global eradication of smallpox. Med J Aust 1 10 (1980) 455-1455
2. Mayr A. Smallpox vaccination and bioterrorism with pox viruses. Comp Immunol Microbiol Infect Dis 26 5-6 (2003) 423-430
3. Slifka M.K. The future of smallpox vaccination: is MVA the key?. Med Immunol 4 1 (2005) 2
4. Mayr A., Stickl H., Muller H.K., Danner K., and Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol [B] 167 5-6 (1978) 375-390
5. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the Modified Vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 2 (1998) 365-396
6. Drexler I., Heller K., Wahren B., Erfle V., and Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79 Pt 2 (1998) 347-352
7. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89 22 (1992) 10847-10851
8. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 16 (2003) 9458-9463
9. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and Modified Vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 1 (2005) 91-101
10. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 2 (2005) 164-175
11. Edghill-Smith Y., Bray M., Whitehouse C.A., Miller D., Mucker E., Manischewitz J., et al. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis 191 3 (2005) 372-381
12. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 27 (2001) 3700-3709
13. Wyatt L.S., Earl P.L., Eller L.A., and Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101 13 (2004) 4590-4595
14. Frey S.E., Newman F.K., Kennedy J.S., Sobek V., Ennis F.A., Hill H., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 25 51 (2007) 8562-8573
15. Parrino J., McCurdy L.H., Larkin B.D., Gordon I.J., Rucker S.E., Enama M.E., et al. Safety, immunogenicity and efficacy of Modified Vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25 8 (2007) 1513-1525
16. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 12 (2006) 2065-2070
17. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H.C., Schafer H., and Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 99 47 (1974) 2386-2392
18. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428 6979 (2004) 182-185
19. Nigam P., Earl P.L., Americo J.L., Sharma S., Wyatt L.S., Edghill-Spano Y., et al. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 366 1 (2007) 73-83
20. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 79 12 (2005) 7845-7851
21. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11 7 (2005) 740-747
22. Smith G.L., Vanderplasschen A., and Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83 Pt 12 (2002) 2915-2931
23. Staib C., Drexler I., and Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 269 (2004) 77-100
24. Santra S., Barouch D.H., Korioth-Schmitz B., Lord C.I., Krivulka G.R., Yu F., et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci USA 101 30 (2004) 11088-11093
25. Santra S., Sun Y., Parvani J.G., Philippon V., Wyand M.S., Manson K., et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 81 16 (2007) 8563-8570
26. Kaufman D.R., Goudsmit J., Holterman L., Ewald B.A., Denholtz M., Devoy C., et al. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol 82 14 (2008) 6829-6837
27. Duke-Cohan J.S., Wollenick K., Witten E., Seaman M.S., Dolin R., and Reinherz E.L. The Heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine 27 (2009) 1154-1165
28. Joachimiak M.P., Weisman J.L., and May B. JColorGrid: software for the visualization of biological measurements. BMC Bioinformatics 7 (2006) 225
29. Lin C.L., Chung C.S., Heine H.G., and Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 74 7 (2000) 3353-3365
30. Hsiao J.C., Chung C.S., and Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 73 10 (1999) 8750-8761
31. Heraud J.M., Edghill-Smith Y., Ayala V., Kalisz I., Parrino J., Kalyanaraman V.S., et al. Subunit recombinant vaccine protects against monkeypox. J Immunol 177 4 (2006) 2552-2564
32. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78 9 (2004) 4433-4443
33. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y., et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79 18 (2005) 11724-11733
34. Berhanu A., Wilson R.L., Kirkwood-Watts D.L., King D.S., Warren T.K., Lund S.A., et al. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 82 7 (2008) 3517-3529
35. Lustig S., Fogg C., Whitbeck J.C., Eisenberg R.J., Cohen G.H., and Moss B. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 79 21 (2005) 13454-13462
36. He Y., Manischewitz J., Meseda C.A., Merchlinsky M., Vassell R.A., Sirota L., et al. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine-induced immunity. J Infect Dis 196 7 (2007) 1026-1032
37. Jones-Trower A., Garcia A., Meseda C.A., He Y., Weiss C., Kumar A., et al. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology 343 1 (2005) 128-140